This phase I trial studies the side effects and best dose of metformin and nelfinavir in treating patients with multiple myeloma that has come back or does not respond to treatment. Metformin may stop the growth of tumor cells by disrupting the energy source within multiple myeloma cells. Nelfinavir may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving metformin and nelfinavir may work better in treating patients with multiple myeloma.
The following criteria is a partial list of reasons why patients may or may not be eligible to participate in this clinical trial. Further evaluation with a medical professional will be required to determine full eligibility.
The following criteria is provided for health care professionals.
There are no resources, links or videos to display for this clinical trial.